Related Experiment Video
Updated: Jun 4, 2026
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
[Prostate-specific antigen for treatment monitoring]
M Graefen1, M Fröhner, M Wirth
1Martini-Klinik, Prostatakarzinom-Zentrum, Universitätsklinik Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Deutschland. graefen@uke.de
Der Urologe. Ausg. A
|March 3, 2011
Abstract:
Today, most incident prostate cancer cases are diagnosed in early and thus potentially curable stages because of the determination of prostate-specific antigen (PSA). Treatment monitoring is another important aspect of the tumor marker PSA. In this article, contemporary recommendations for the use of PSA in treatment monitoring are discussed in the settings of active surveillance, radical prostatectomy and radiotherapy.
